Pulmocide Presents at US FDA Workshop on Inhaled Antifungal Drug Development

London, UK, 26 October 2020 – Pulmocide Ltd, which is developing first-in-class inhaled anti-infectives initially for targeted treatment of life-threatening lung infections, is pleased to announce that the company was invited to present at the The Food and Drug Administration (FDA) virtual public workshop entitled “Addressing Challenges in Inhaled Antifungal Drug Development” on 25 September 2020. The purpose of the virtual public workshop was to discuss the challenges and clinical trial design considerations for developing inhaled antifungal drugs. Dr. Lance Berman, Chief Medical Officer, presented on PC945 in his talk “A Novel Inhaled Azole for Invasive Pulmonary Aspergillosis: Clinical and Regulatory Opportunities and Challenges.”

All presentations from the workshop, a transcript, and recordings can be found here.

Scroll to Top